HRP20201489T1 - Imunoglobulini konjugirani s cys80 - Google Patents

Imunoglobulini konjugirani s cys80 Download PDF

Info

Publication number
HRP20201489T1
HRP20201489T1 HRP20201489TT HRP20201489T HRP20201489T1 HR P20201489 T1 HRP20201489 T1 HR P20201489T1 HR P20201489T T HRP20201489T T HR P20201489TT HR P20201489 T HRP20201489 T HR P20201489T HR P20201489 T1 HRP20201489 T1 HR P20201489T1
Authority
HR
Croatia
Prior art keywords
seq
variable region
chain variable
immunoglobulin
light chain
Prior art date
Application number
HRP20201489TT
Other languages
English (en)
Inventor
Luigi Grasso
Jared Spidel
James Bradford Kline
Earl Albone
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of HRP20201489T1 publication Critical patent/HRP20201489T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Claims (19)

1. Postupak dobivanja konjugiranog imunoglobulina, naznačen time što se postupak sastoji u: skidanju kape s cisteina na aminokiselinskom položaju 80 ("Cys80") u varijabilnom području lakog lanca imunoglobulina dobivenog iz kunića, gdje se Cys80 bazira na sustavu obrojčavanja prema Kabatu ili Chothiji, gdje imunoglobulin sadrži varijabilno područje teškog lanca i varijabilno područje lakog lanca; i konjugiranju spoja koji reagira s tiolom s Cys80, gdje spoj koji reagira s tiolom sadrži skupinu koja reagira s tiolom.
2. Postupak u skladu s patentnim zahtjevom 1, naznačen time što se skidanje kape sastoji u inkubiranju imunoglobulina s reducirajućim puferom, za čim slijedi inkubiranje imunoglobulina s oksidirajućim puferom.
3. Postupak u skladu s patentnim zahtjevom 2, naznačen time što postupak dodatno uključuje imobiliziranje imunoglobulina na matriksu prije inkubiranja s reducirajućim puferom i eluiranja imunoglobulina iz matriksa nakon inkubiranja s oksidirajućim puferom.
4. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što (a) spoj koji reagira s tiolom je vezan na funkcionalno sredstvo, gdje funkcionalno sredstvo uključuje fluorofor, fluorescentno bojilo, polipeptid, imunoglobulin, antibiotik, nukleinsku kiselinu, radionuklid, kemijsku spojnicu, malu molekulu, kelator, lipid ili lijek, i/ili (b) spoj koji reagira s tiolom je vezan na drugi spoj koji reagira s tiolom, gdje je drugi spoj koji reagira s tiolom vezan na drugi imunoglobulin koji ima drugo varijabilno područje teškog lanca i drugo varijabilno područje lakog lanca, gdje drugo varijabilno područje lakog lanca ima cistein na aminokiselinskom položaju 80 ("Cys802"), gdje se Cys802 bazira na sustavu obrojčavanja prema Kabatu ili Chothiji, gdje drugi spoj koji reagira s tiolom sadrži drugu skupinu koja reagira s tiolom vezanim na Cys802, i/ili (c) Cys80 nije sparen, i/ili (d) postupak dodatno uključuje zamjenu aminokiseline na položaju 83 aminokiselinskim ostatkom koji nije Phe, Lys ili Cys, gdje se položaj 83 bazira na sustavu obrojčavanja prema Kabatu ili Chothiji.
5. Postupak dobivanja molekule koja se veže na antigen, naznačen time što se postupak sastoji u inkubiranju prvog konjugiranog imunoglobulina s drugim konjugiranim imunoglobulinom kako bi se dobilo molekulu koja se veže na antigen, gdje: prvi konjugirani imunoglobulin sadrži prvo varijabilno područje teškog lanca i prvo varijabilno područje lakog lanca, gdje prvo varijabilno područje lakog lanca ima cistein na položaju 80 ("Cys801"), gdje je Cys801 konjugiran s prvim spojem koji reagira s tiolom koji sadrži prvu skupinu koja reagira s tiolom, te gdje je imunoglobulin dobiven iz kunića, a Cys801 se bazira na sustavu obrojčavanja prema Kabatu ili Chothiji; i drugi konjugirani imunoglobulin sadrži drugo varijabilno područje teškog lanca i drugo varijabilno područje lakog lanca, gdje drugo varijabilno područje lakog lanca ima cistein na položaju 80 ("Cys802"), gdje je Cys802 konjugiran s drugim spojem koji reagira s tiolom koji sadrži drugu skupinu koja reagira s tiolom, te gdje je imunoglobulin dobiven iz kunića, a Cys802 se bazira na sustavu obrojčavanja prema Kabatu ili Chothiji.
6. Postupak u skladu s patentnim zahtjevom 5, naznačen tme što (a) Cys801, Cys802, ili oba, nije sparen, i/ili (b) postupak dodatno uključuje, prije koraka inkubiranja, skidanje kape s Cys801, Cys802, ili oba; i konjugiranje prvog spoja koji reagira s tiolom s Cys801, drugog spoja koji reagira s tiolom s Cys802, ili oba, gdje prvi spoj koji reagira s tiolom sadrži prvu skupinu koja reagira s tiolom i drugi spoj koji reagira s tiolom sadrži drugu skupinu koja reagira s tiolom.
7. Postupak u skladu s bilo kojim od patentnih zahtjeva 5-6, naznačen time što (a) prvi spoj koji reagira s tiolom dodatno sadrži prvo funkcionalno sredstvo, drugi spoj koji reagira s tiolom dodatno sadrži drugo funkcionalno sredstvo, ili oba, i/ili (b) prvi imunoglobulin je prvi Fab, drugi imunoglobulin je drugi Fab, ili oba, i/ili (c) postupak dodatno uključuje zamjenu aminokiseline na položaju 83 u prvom varijabilnom području lakog lanca aminokiselinskim ostatkom koji nije Phe, Lys ili Cys, zamjenu aminokiseline na položaju 83 u drugom varijabilnom području lakog lanca aminokiselinskim ostatkom koji nije Phe, Lys ili Cys, ili obje.
8. Molekula koja se veže na antigen, naznačena time što ju se proizvodi postupkom u skladu s bilo kojim od patentnih zahtjeva 5-7.
9. Imunoglobulin dobiven iz kunića naznačen time što sadrži varijabilno područje teškog lanca i varijabilno područje lakog lanca, gdje varijabilno područje lakog lanca ima cistein na položaju 80 ("Cys80"), gdje Cys80 nije sparen, i aminokiselinu koja nije Phe, Lys ili Cys na položaju 83, te gdje se Cys80 i položaj 83 baziraju na sustavu obrojčavanja prema Kabatu ili Chothiji.
10. Imunoglobulin u skladu s patentnim zahtjevom 9, naznačen time što je s Cys80 skinuta kapa.
11. Imunoglobulin u skladu s patentnim zahtjevom 9 ili 10, naznačen time što: (A) imunoglobulin se imunospecifično veže na ljudski CA9 i sadrži: a. varijabilno područje teškog lanca koje sadrži aminokiseline 20-141 u xil55D5HC (SEQ ID NO:52) i varijabilno područje lakog lanca koje sadrži aminokiseline 20-130 u xil55D5LC (SEQ ID NO:78); b. varijabilno područje teškog lanca koje sadrži aminokiseline 20-144 u zul55D5HC (SEQ ID NO:54) i varijabilno područje lakog lanca koje sadrži aminokiseline 20-130 u zul55D5LC-3 (SEQ ID NO:84), zul55D5LC-4 (SEQ ID NO:86), zul55D5LC-5 (SEQ ID NO:88), zul55D5LC-6 (SEQ ID NO:90), zul55D5LC-7 (SEQ ID NO:92), zu155D5LC-huVK2-40 (SEQ ID NO:96), zu155D5LC-huVK4-1 (SEQ ID NO:100), zu155D5LChuVK6-21 (SEQ ID NO:102), zu155D5LC-huVK6D-41 (SEQ ID NO:104); ili zu155D5LC-huVK7-3-Glu8l (SEQ ID NO:106); c. varijabilno područje teškog lanca koje sadrži aminokiseline 20-138 u xi1E4HC (SEQ ID NO:58) i varijabilno područje lakog lanca koje sadrži aminokiseline 20-130 u xi1E4LC (SEQ ID NO:110); d. varijabilno područje teškog lanca koje sadrži aminokiseline 20-140 u zu1E4HC (SEQ ID NO:60) i varijabilno područje lakog lanca koje sadrži aminokiseline 20-130 u zu1E4LC-CXXA (SEQ ID NO:114); e. varijabilno područje teškog lanca koje sadrži aminokiseline 20-142 u xi166B3HC (SEQ ID NO:74) i varijabilno područje lakog lanca koje sadrži aminokiseline 20-130 u xi166B3LC (SEQ ID NO:132); ili f. varijabilno područje teškog lanca koje sadrži aminokiseline 20-145 u zu166B3HC (SEQ ID NO:76) i varijabilno područje lakog lanca koje sadrži aminokiseline 20-130 u zu166B3LC-CXXA (SEQ ID NO:136), ili (B) imunoglobulin se imunospecifično veže na ljudski CA9 i sadrži: a. CDR1, CDR2, te CDR3 teškog lanca u xi155D5HC, kao što je iznijeto u SEQ ID NO:146, 148, i 150, odnosno, i CDR1, CDR2, te CDR3 lakog lanca u xil55D5LC, kao što je iznijeto u SEQ ID NO:224, 226, i 228, odnosno; b. CDR1, CDR2, te CDR3 teškog lanca u zul55D5HC, kao što je iznijeto u SEQ ID NO:152, 154, odnosno 156, i CDR1, CDR2, te CDR3 lakog lanca u zu155D5LC-3, kao što je iznijeto u SEQ ID NO:242, 244, odnosno 246, zu155D5LC-4, kao što je iznijeto u SEQ ID NO:248, 250, odnosno 252, zu155D5LC-5, kao što je iznijeto u SEQ ID NO:254, 256, odnosno 258, zu155D5LC-6, kao što je iznijeto u SEQ ID NO:260, 262, odnosno 264, zu155D5LC-7, kao što je iznijeto u SEQ ID NO:266, 268, odnosno 270, zu155D5LC-huVK2-40, kao što je iznijeto u SEQ ID NO: 278, 280, odnosno 282, zu155D5LC-huVK4-1, kao što je iznijeto u SEQ ID NO: 290, 292, odnosno 294, zu155D5LC-huVK6-21, kao što je iznijeto u SEQ ID NO: 296, 298, odnosno 300, zu155D5LC-huVK6D-41, kao što je iznijeto u SEQ ID NO: 302, 304, odnosno 306; ili zu155D5LC-huVK7-3-Glu81, kao što je iznijeto u SEQ ID NO: 308, 310, odnosno 312; c. CDR1, CDR2, te CDR3 teškog lanca u xi1E4HC, kao što je iznijeto u SEQ ID: NO:164, 166, odnosno 168, i CDR1, CDR2, te CDR3 lakog lanca u xi1E4LC, kao što je iznijeto u SEQ ID NO:320, 322, odnosno 324; d. CDR1, CDR2, te CDR3 teškog lanca u zu1E4HC, kao što je iznijeto u SEQ ID NO:170, 172, odnosno 174, i CDR1, CDR2, te CDR3 lakog lanca u zu1E4LC-CXXA, kao što je iznijeto u SEQ ID NO:332, 334, odnosno 336; e. CDR1, CDR2, te CDR3 teškog lanca u xi166B3HC, kao što je iznijeto u SEQ ID NO:212, 214, odnosno 216, i CDR1, CDR2, te CDR3 lakog lanca u xil66B3LC, kao što je iznijeto u SEQ ID NO:386, 388, odnosno 390; ili f. CDR1, CDR2, te CDR3 teškog lanca u zu166B3HC, kao što je iznijeto u SEQ ID NO:218, 220, odnosno 222, i CDR1, CDR2, te CDR3 lakog lanca u zu166B3LC-CXXA, kao što je iznijeto u SEQ ID NO:398, 400, odnosno 402, ili (C) imunoglobulin se imunospecifično veže na ljudski TEM1 i sadrži varijabilno područje teškog lanca koje sadrži aminokiseline 20-139 u xi1-55-2HC (SEQ ID NO:56) i varijabilno područje lakog lanca koje sadrži aminokiseline 20-129 u xi1-55-2LC (SEQ ID NO:108), ili (D) imunoglobulin se imunospecifično veže na ljudski TEM1 i sadrži CDR1, CDR2, te CDR3 teškog lanca u xi1-55-2HC, kao što je iznijeto u SEQ ID NO: 158, 160, odnosno 162, i CDR1, CDR2, te CDR3 lakog lanca u xi1-55-2LC, kao što je iznijeto u SEQ ID NO:314, 316, odnosno 318, ili (E) imunoglobulin se imunospecifično veže na ljudski mezotelin i sadrži: a. varijabilno područje teškog lanca koje sadrži aminokiseline 20-142 u xi33011HC (SEQ ID NO:62) i varijabilno područje lakog lanca koje sadrži aminokiseline 20-131 u xi33011LC (SEQ ID NO:116); b. varijabilno područje teškog lanca koje sadrži aminokiseline 20-145 u zu33011HC (SEQ ID NO:64) i varijabilno područje lakog lanca koje sadrži aminokiseline 20-131 u zu33O11LC-CXXA (SEQ ID NO:120) ili zu33011LCCXXI (SEQ ID NO:122); c. varijabilno područje teškog lanca koje sadrži aminokiseline 20-137 u xi324O5HC (SEQ ID NO:66) i varijabilno područje lakog lanca koje sadrži aminokiseline 20-127 u xi324O5LC (SEQ ID NO:124); d. varijabilno područje teškog lanca koje sadrži aminokiseline 20-137 u xi178F16HC (SEQ ID NO:68) i varijabilno područje lakog lanca koje sadrži aminokiseline 20-127 u xi178F16LC (SEQ ID NO:126); e. varijabilno područje teškog lanca koje sadrži aminokiseline 20-132 u xi237N18HC (SEQ ID NO:70) i varijabilno područje lakog lanca koje sadrži aminokiseline 20-127 u xi237N18LC (SEQ ID NO:128); ili f. varijabilno područje teškog lanca koje sadrži aminokiseline 20-137 u xi383I18HC (SEQ ID NO:72) i varijabilno područje lakog lanca koje sadrži aminokiseline 20-127 u xi383I18LC (SEQ ID NO:130), ili (F) imunoglobulin se imunospecifično veže na ljudski mezotelin i sadrži: a. CDR1, CDR2, te CDR3 teškog lanca u xi33011HC, kao što je iznijeto u SEQ ID NO: 176, 178, odnosno 180, i CDR1, CDR2, te CDR3 lakog lanca u xi33011LC, kao što je iznijeto u SEQ ID NO:338, 340, odnosno 342; b. CDR1, CDR2, te CDR3 teškog lanca u zu33011HC, kao što je iznijeto u SEQ ID NO:182, 184, odnosno 186, i CDR1, CDR2, te CDR3 lakog lanca u zu33O11LC-CXXA, kao što je iznijeto u SEQ ID NO:350, 352, odnosno 354, ili zu33011LC-CXXI, kao što je iznijeto u SEQ ID NO:356, 358, odnosno 360; c. CDR1, CDR2, te CDR3 teškog lanca u xi324O5HC, kao što je iznijeto u SEQ ID NO:188, 190, odnosno 192, i CDR1, CDR2, te CDR3 lakog lanca u xi324O5LC, kao što je iznijeto u SEQ ID NO:362, 364, odnosno 366; d. CDR1, CDR2, te CDR3 teškog lanca u xi178F16HC, kao što je iznijeto u SEQ ID NO:194, 196, odnosno 198, i CDR1, CDR2, te CDR3 lakog lanca u xi178F16LC, kao što je iznijeto u SEQ ID NO:368, 370, odnosno 372; e. CDR1, CDR2, te CDR3 teškog lanca u xi237N18HC, kao što je iznijeto u SEQ ID NO:200, 202, odnosno 204, i CDR1, CDR2, te CDR3 lakog lanca u xi237N18LC, kao što je iznijeto u SEQ ID NO:374, 376, odnosno 378; ili f. CDR1, CDR2, te CDR3 teškog lanca u xi383I18HC, kao što je iznijeto u SEQ ID NO:206, 208, odnosno 210, i CDR1, CDR2, te CDR3 lakog lanca u xi383I18LC, kao što je iznijeto u SEQ ID NO:380, 382, odnosno 384.
12. Konjugirani imunoglobulin, naznačen time što sadrži: imunoglobulin u skladu s bilo kojim od patentnih zahtjeva 9-11, gdje je cistein na položaju 80 konjugiran sa spojem koji reagira s tiolom, gdje spoj koji reagira s tiolom koji sadrži skupinu koja reagira s tiolom.
13. Konjugirani imunoglobulin u skladu s patentnim zahtjevom 12, naznačen time što spoj koji reagira s tiolom dodatno sadrži funkcionalno sredstvo, gdje funkcionalno sredstvo uključuje fluorofor, fluorescentno bojilo, polipeptid, imunoglobulin, antibiotik, nukleinsku kiselinu, radionuklid, kemijsku spojnicu, malu molekulu, kelator, lipid ili lijek.
14. Konjugirani imunoglobulin protiv mezotelina namijenjen upotrebi u postupku liječenja raka kod subjekta, naznačen time što konjugirani imunoglobulin protiv mezotelina sadrži: imunoglobulin u skladu s patentnim zahtjevom 11(E) ili 11(F), i spoj koji reagira s tiolom koji sadrži skupinu koja reagira s tiolom, spojnicu, te funkcionalno sredstvo, gdje funkcionalno sredstvo uključuje fluorofor, fluorescentno bojilo, polipeptid, imunoglobulin, antibiotik, nukleinsku kiselinu, radionuklid, kemijsku spojnicu, malu molekulu, kelator, lipid ili lijek.
15. Konjugirani imunoglobulin protiv mezotelina namijenjen upotrebi u skladu s patentnim zahtjevom 14, naznačen time što je funkcionalno sredstvo auristatin F.
16. Molekula koja se veže na antigen, naznačena time što sadrži: prvi konjugirani imunoglobulin, koji sadrži prvo varijabilno područje teškog lanca i prvo varijabilno područje lakog lanca, gdje prvo varijabilno područje lakog lanca ima cistein na položaju 80 ("Cys801"), gdje je Cys801 konjugiran s prvim spojem koji reagira s tiolom koji sadrži prvu skupinu koja reagira s tiolom, te gdje je imunoglobulin dobiven iz kunića, a Cys801 se bazira na sustavu obrojčavanja prema Kabatu ili Chothiji, i drugi konjugirani imunoglobulin, koji sadrži drugo varijabilno područje teškog lanca i drugo varijabilno područje lakog lanca, gdje drugo varijabilno područje lakog lanca ima cistein na položaju 80 ("Cys802"), gdje je Cys802 konjugiran s drugim spojem koji reagira s tiolom koji sadrži drugu skupinu koja reagira s tiolom, te gdje je imunoglobulin dobiven iz kunića, a Cys802 se bazira na sustavu obrojčavanja prema Kabatu ili Chothiji.
17. Molekula koja se veže na antigen u skladu s patentnim zahtjevom 16, naznačena time što (a) Cys801, Cys802, ili oba, nije sparen, i/ili (b) aminokiselina na položaju 83 u prvom imunoglobulinu, aminokiselina na položaju 83 u drugom imunoglobulinu, ili obje, je aminokiselinski ostatak koji nije Phe, Lys ili Cys, gdje se položaj 83 bazira na sustavu obrojčavanja prema Kabatu ili Chothiji, i/ili (c) prvi spoj koji reagira s tiolom dodatno sadrži prvo funkcionalno sredstvo, drugi spoj koji reagira s tiolom dodatno sadrži drugo funkcionalno sredstvo, ili oba, gdje prvo i drugo funkcionalno sredstvo uključuju fluorofor, fluorescentno bojilo, polipeptid, imunoglobulin, antibiotik, nukleinsku kiselinu, radionuklid, kemijsku spojnicu, malu molekulu, kelator, lipid ili lijek, i/ili (d) prvi imunoglobulin, drugi imunoglobulin, ili oba, je Fab.
18. Molekula nukleinske kiseline, naznačena time što kodira imunoglobulin u skladu s bilo kojim od patentnih zahtjeva 9-11.
19. Stanica domaćin, naznačena time što sadrži molekulu nukleinske kiseline u skladu s patentnim zahtjevom 18.
HRP20201489TT 2015-06-19 2020-09-18 Imunoglobulini konjugirani s cys80 HRP20201489T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562182020P 2015-06-19 2015-06-19
PCT/US2016/038041 WO2016205618A1 (en) 2015-06-19 2016-06-17 Cys80 conjugated immunoglobulins
EP16736952.9A EP3310816B1 (en) 2015-06-19 2016-06-17 Cys80 conjugated immunoglobulins

Publications (1)

Publication Number Publication Date
HRP20201489T1 true HRP20201489T1 (hr) 2020-12-11

Family

ID=56404289

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201489TT HRP20201489T1 (hr) 2015-06-19 2020-09-18 Imunoglobulini konjugirani s cys80

Country Status (33)

Country Link
US (3) US10273310B2 (hr)
EP (2) EP3795591B1 (hr)
JP (2) JP6823606B2 (hr)
KR (1) KR20180021807A (hr)
CN (1) CN107949575B (hr)
AU (1) AU2016280190B9 (hr)
BR (1) BR112017027252A2 (hr)
CA (1) CA2989637C (hr)
CL (1) CL2017003273A1 (hr)
CO (1) CO2017013303A2 (hr)
CY (1) CY1123481T1 (hr)
DK (2) DK3310816T3 (hr)
ES (2) ES2829251T3 (hr)
HK (1) HK1252625A1 (hr)
HR (1) HRP20201489T1 (hr)
HU (2) HUE064407T2 (hr)
IL (1) IL256263B (hr)
LT (1) LT3310816T (hr)
MA (1) MA44207B1 (hr)
MD (1) MD3310816T2 (hr)
MX (1) MX2017016674A (hr)
MY (1) MY189024A (hr)
PE (1) PE20180498A1 (hr)
PH (1) PH12017502352A1 (hr)
PL (1) PL3310816T3 (hr)
PT (1) PT3310816T (hr)
RS (1) RS60943B1 (hr)
RU (1) RU2756101C2 (hr)
SG (1) SG10201913935RA (hr)
SI (1) SI3310816T1 (hr)
UA (1) UA124830C2 (hr)
WO (1) WO2016205618A1 (hr)
ZA (2) ZA201708619B (hr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4055053A1 (en) 2019-11-07 2022-09-14 Eisai R&D Management Co., Ltd. Anti-mesothelin eribulin antibody-drug conjugates and methods of use
JP7399305B2 (ja) * 2020-02-12 2023-12-15 イーライ リリー アンド カンパニー 抗体または抗原結合フラグメントの結晶化
CA3184645A1 (en) 2020-06-05 2021-12-09 Eisai R&D Management Co., Ltd. Anti-bcma antibody-drug conjugates and methods of use
CN112694521B (zh) * 2020-12-02 2023-01-17 杭州百凌生物科技有限公司 一种人工多肽lh、其抗体及在病理检测中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1187094C (zh) * 1998-04-28 2005-02-02 应用研究系统Ars股份公司 多元醇干扰素β偶联物
US6904369B1 (en) * 2000-06-29 2005-06-07 The Trustees Of Columbia University In The City Of New York Conjugated ligands for the stimulation of blood cell proliferation by effecting dimerization of the receptor for stem cell factor
US7402409B2 (en) 2003-01-23 2008-07-22 Epitomics, Inc. Cell fusion method
AU2003259718A1 (en) 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
WO2006017759A2 (en) * 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
JP5791895B2 (ja) * 2007-05-04 2015-10-07 テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー 遺伝子操作されたウサギ抗体可変ドメイン及びその使用
EP2162469A4 (en) * 2007-05-21 2012-08-01 Alderbio Holdings Llc NEW METHODS OF HUMANIZING RABBIT ANTIBODIES AND HUMANIZED RABBIT ANTIBODIES
US20110033378A1 (en) * 2008-01-18 2011-02-10 Medlmmune, Llc. Cysteine Engineered Antibodies For Site-Specific Conjugation
EP2842575B1 (en) 2008-03-18 2017-09-27 Seattle Genetics, Inc. Auristatin drug linker conjugates
WO2010118203A2 (en) 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules
CN114246952A (zh) * 2010-06-08 2022-03-29 基因泰克公司 半胱氨酸改造的抗体和偶联物
AR082205A1 (es) * 2010-07-12 2012-11-21 Covx Technologies Ireland Ltd Conjugados de anticuerpos multifuncionales
CN102008732B (zh) * 2010-11-08 2012-10-24 武汉华耀生物医药有限公司 一种叶酸偶联抗体药物及其制备方法与应用
CA2882753C (en) 2012-08-21 2021-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
RS58928B1 (sr) * 2012-08-29 2019-08-30 Hoffmann La Roche Transporter za krvno-moždanu barijeru
EP3892294A1 (en) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions

Also Published As

Publication number Publication date
IL256263B (en) 2022-06-01
PH12017502352A1 (en) 2018-06-25
PE20180498A1 (es) 2018-03-09
MX2017016674A (es) 2018-08-01
AU2016280190B9 (en) 2022-05-19
MA44207B1 (fr) 2020-11-30
JP6823606B2 (ja) 2021-02-03
AU2016280190B2 (en) 2022-04-28
CN107949575A (zh) 2018-04-20
DK3310816T3 (da) 2020-10-12
HUE051315T2 (hu) 2021-03-01
ZA201708619B (en) 2022-11-30
ES2967613T3 (es) 2024-05-03
KR20180021807A (ko) 2018-03-05
RU2017146220A (ru) 2019-07-19
LT3310816T (lt) 2020-11-25
US20190202933A1 (en) 2019-07-04
HK1252625A1 (zh) 2019-05-31
CY1123481T1 (el) 2022-03-24
IL256263A (en) 2018-02-28
NZ738496A (en) 2023-08-25
RU2756101C2 (ru) 2021-09-28
CO2017013303A2 (es) 2018-03-20
US11129904B2 (en) 2021-09-28
MY189024A (en) 2022-01-20
SG10201913935RA (en) 2020-03-30
ZA202102093B (en) 2023-03-29
PT3310816T (pt) 2020-10-19
US20230001004A1 (en) 2023-01-05
EP3310816A1 (en) 2018-04-25
BR112017027252A2 (pt) 2018-08-28
JP7042876B2 (ja) 2022-03-28
EP3310816B1 (en) 2020-09-09
RS60943B1 (sr) 2020-11-30
MD3310816T2 (ro) 2021-01-31
UA124830C2 (uk) 2021-12-01
MA44207A (fr) 2018-12-26
HUE064407T2 (hu) 2024-03-28
US10273310B2 (en) 2019-04-30
SI3310816T1 (sl) 2020-12-31
CA2989637A1 (en) 2016-12-22
CN107949575B (zh) 2022-03-08
US20160369011A1 (en) 2016-12-22
EP3795591B1 (en) 2023-09-27
CA2989637C (en) 2023-01-10
CL2017003273A1 (es) 2018-12-21
ES2829251T3 (es) 2021-05-31
JP2020178717A (ja) 2020-11-05
WO2016205618A1 (en) 2016-12-22
RU2017146220A3 (hr) 2019-11-07
PL3310816T3 (pl) 2020-12-14
AU2016280190A1 (en) 2018-01-18
EP3795591A1 (en) 2021-03-24
DK3795591T3 (da) 2024-01-02
JP2018526975A (ja) 2018-09-20

Similar Documents

Publication Publication Date Title
HRP20201489T1 (hr) Imunoglobulini konjugirani s cys80
HRP20180352T1 (hr) Protutijela anti-fcrh5
HRP20201747T1 (hr) Bispecifične antigen vezujuće molekule koje aktiviraju t stanice, protiv folr1 i cd3
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
HRP20181087T1 (hr) Pripravak i postupak dijagnostike i liječenja bolesti povezanih s degeneracijom neurita
CN113045660B (zh) 与cd8的抗原结合构建体
HRP20161146T1 (hr) Anti-c5 antitijela s poboljšanom farmakokinetikom
RU2017145653A (ru) Средства, пути применения и способы лечения синуклеопатии
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
PE20190976A1 (es) Anticuerpos de union a cd3
PE20210377A1 (es) Anticuerpos anti-pd-l1 y usos de los mismos
HRP20171067T1 (hr) Terapeutska upotreba specifičnih liganda u bolestima povezanim sa msrv
RU2016100892A (ru) Антитела против tweakr и их применение
PE20090329A1 (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
AR053514A1 (es) Anticuerpos dirigidos contra cd20 y sus usos
EP2796466A3 (en) Humanized antibody molecules specific for IL-31
HRP20110599T1 (hr) Antitijela protiv toksina clostridium difficile i njihove primjene
JP2020124203A (ja) 血液脳関門輸送分子およびそれらの使用
CN109071637A (zh) 结合严重发热伴血小板减少综合征病毒的包膜糖蛋白的抗体及其用途
HRP20202047T1 (hr) Antitijelo za igf-1r i njegova upotreba kao usmjeravajućeg vezikula za liječenje karcinoma
BR0207151A (pt) Moléculas de aglutinação terapêuticas
JP2019533426A5 (hr)
WO2022032023A3 (en) Il23r binding molecules and methods of use
JP2018519804A5 (hr)